Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.

Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni GB, Galluzzi S, Perneczky R, Drzezga A, van Berckel BN, Ossenkoppele R, Didic M, Guedj E, Brugnolo A, Picco A, Arnaldi D, Ferrara M, Buschiazzo A, Sambuceti G, Nobili F.

Neuroimage Clin. 2014 Nov 18;7:34-42. doi: 10.1016/j.nicl.2014.11.007.

2.

Imaging biomarkers associated with cognitive decline: a review.

McConathy J, Sheline YI.

Biol Psychiatry. 2015 Apr 15;77(8):685-92. doi: 10.1016/j.biopsych.2014.08.024. Review.

3.

Primary age-related tauopathy (PART): a common pathology associated with human aging.

Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL 3rd, Wisniewski T, Woltjer RL, Yamada M, Nelson PT.

Acta Neuropathol. 2014 Dec;128(6):755-66. doi: 10.1007/s00401-014-1349-0.

4.

Does past or present depression differentiate Lewy body from Alzheimer disease?

Falkowski J, Hynan LS, Womack KB, Hatanpaa KJ, White CL 3rd, Weiner MF.

Int Psychogeriatr. 2015 Apr;27(4):693-4. doi: 10.1017/S1041610214001793. No abstract available.

5.

Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database.

Gaugler JE, Ascher-Svanum H, Roth DL, Fafowora T, Siderowf A, Beach TG.

BMC Geriatr. 2013 Dec 19;13:137. doi: 10.1186/1471-2318-13-137.

6.

Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.

Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, Kung MP, Wey SP, Hsieh CJ, Wai YY, Yen TC, Huang CC.

PLoS One. 2013;8(3):e58974. doi: 10.1371/journal.pone.0058974.

7.

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.

Guo S, Getsios D, Hernandez L, Cho K, Lawler E, Altincatal A, Lanes S, Blankenburg M.

Int J Alzheimers Dis. 2012;2012:548157. doi: 10.1155/2012/548157.

8.

Amyloid deposition, hypometabolism, and longitudinal cognitive decline.

Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative..

Ann Neurol. 2012 Oct;72(4):578-86. doi: 10.1002/ana.23650.

9.

Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning.

Eskildsen SF, Coupé P, García-Lorenzo D, Fonov V, Pruessner JC, Collins DL; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2013 Jan 15;65:511-21. doi: 10.1016/j.neuroimage.2012.09.058.

10.

Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease.

Gray KR, Wolz R, Heckemann RA, Aljabar P, Hammers A, Rueckert D; Alzheimer's Disease Neuroimaging Initiative..

Neuroimage. 2012 Mar;60(1):221-9. doi: 10.1016/j.neuroimage.2011.12.071.

11.

Videoconference diagnosis and management of Choctaw Indian dementia patients.

Weiner MF, Rossetti HC, Harrah K.

Alzheimers Dement. 2011 Nov;7(6):562-6. doi: 10.1016/j.jalz.2011.02.006.

12.

Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera.

Nagele E, Han M, Demarshall C, Belinka B, Nagele R.

PLoS One. 2011;6(8):e23112. doi: 10.1371/journal.pone.0023112.

13.

Luria's three-step test: what is it and what does it tell us?

Weiner MF, Hynan LS, Rossetti H, Falkowski J.

Int Psychogeriatr. 2011 Dec;23(10):1602-6. doi: 10.1017/S1041610211000767.

14.

PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease.

Pontecorvo MJ, Mintun MA.

Alzheimers Res Ther. 2011 Mar 29;3(2):11. doi: 10.1186/alzrt70.

15.

Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease.

Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Santacruz K, Smith CD, Patel E, Markesbery WR.

J Neuropathol Exp Neurol. 2009 Jul;68(7):774-84. doi: 10.1097/NEN.0b013e3181aacbe9.

16.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

17.

Language in Alzheimer's disease.

Weiner MF, Neubecker KE, Bret ME, Hynan LS.

J Clin Psychiatry. 2008 Aug;69(8):1223-7.

Supplemental Content

Support Center